Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
This story is reported by Yahoo Finance. Read what other outlets are saying below, then open the original report for full details.